Synonym |
Thai / English name |
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12N(Treatment) : 12Sex : -Age : 20-36 yrsRoute : Oral administrationDose/Conc.(herb) : 2 tablets x 3 times dailyDuration : 1 week with at least 14-day washoutType of interaction : PharmacodynamicsInteraction with drug : WarfarinDose/Conc.(drug) : -Result : NegativeRemark : The mean ratios of the AUCO-168 of INR were 0.93 (0.82-1.05) following treatment with ginkgo and 1.03 (0.90-1.15) for ginger treatment. These data suggest there is no significant effect of these herbs on warfarin pharmacodynamics. Neither ginkgo nor ginger alone affected baseline INR or ex vivo platelet aggregation in response to arachidonic acid.Note : Each ginger tablet containing 0.4 g of ginger rhizome powder Each Gingko tablet equivalent to 2 g of Ginkgo biloba leaf (9.6 mg of ginkgo flavonglycosides, 2.4 mg of ginkgolides and bilobalide)
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 12N(Treatment) : 12Sex : MaleAge : 20-36 yrsRoute : Oral administrationDose/Conc.(herb) : 2 tablets x 3 times dailyDuration : 1 week with at least 14-day washoutType of interaction : PharmacodynamicsInteraction with drug : WarfarinDose/Conc.(drug) : -Result : NegativeRemark : There were no significant changes observed in the pharmacokinetic parameters of S- or R-warfarin in healthy male subjects following treatment with ginkgo or ginger. The urinary excretion rate of S-7-hydroxywarfarin after administration of warfarin alone was no significant difference following treatment with either ginkgo or ginger.Note : Each ginger tablet containing 0.4 g of ginger rhizome powder Each Gingko tablet equivalent to 2 g of Ginkgo biloba leaf (9.6 mg of ginkgo flavonglycosides, 2.4 mg of ginkgolides and bilobalide)
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : EGb761Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 50 (M/F=50/-)N(Treatment) : 50 (M/F=50/-)Sex : MaleAge : 20-44 yrs. (mean 27.2+/-4.9)Route : Oral administrationDose/Conc.(herb) : EGb 761 120 mg of dry extract twice dailyDuration : 7 daysType of interaction : PharmacokineticsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : 500 mg dailyResult : PositiveRemark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : EGb761Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 50 (M/F=50/-)N(Treatment) : 50 (M/F=50/-)Sex : MaleAge : 20-44 yrs. (mean 27.2+/-4.9)Route : Oral administrationDose/Conc.(herb) : EGb 761 120 mg of dry extract twice dailyDuration : 7 daysType of interaction : PharmacokineticsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : 500 mg dailyResult : PositiveRemark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : Ginkgo biloba special extraction (EGb 761)Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 50N(Treatment) : 50Sex : MaleAge : 20-44 yearsRoute : Oral administrationDose/Conc.(herb) : *Duration : **Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : EquivocalRemark : Results: Acetylsalicylic acid (ASA) and the combination of ASA +EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of means 1.01, 90% Cl 0.86, 1.19) and agonist - induced platelet aggregation (collagen - induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00, 90% Cl 0.95, 1.05; ADP-induced platelet aggregation -ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06).Note : *Dose: Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo - coated tablate in the morning and placebo tablet + placebo - coated tablet in evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg - coated tablet in the morning and placebo tablet + EGb 761 120 mg - coated tablet in evening. **Duration: Each treatment lasted 7 days, the washout period between treatment was 3 weeks. - Data incomplete.
Part Used : ใบActivity : PLATELET AGGREGATION INHIBITIONSolvent/Active Compound : Ginkgo biloba leaf ext. (GBE)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Effect of GBE on PAF (25, 50 , 100, 200 and 1,000 micrograms/L-1) induced platelet aggregation was estimated by preincubation cryopreserved human primary hepatocytes (HPHs) with GBE before the addition of PAF.Duration : -Type of interaction : PharmacodynamicsInteraction with drug : -Dose/Conc.(drug) : Platelet activating factor (PAF) 25, 50, 100, 200 and 1,000 micrograms/L-1.Result : PositiveRemark :Note : Result: GBE showed the inhibition of PAF-induced platelet aggregation with IC50 of 33 mg/L-1, 30% enhancement over the control. These effects of GBE were reduced significantly by selectively inhibiting CYP1A2 but CYP2B6, 2C19, 2E1 and 3A4. The inhibitive effects of GBE on PAF induced platelet aggregation are regulated by CYP1A2. Data incomplete.